{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:44:38Z","timestamp":1793821478350,"version":"4.6.1"},"reference-count":179,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.phrs.2026.108107","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T07:47:13Z","timestamp":1769240833000},"page":"108107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update"],"prefix":"10.1016","volume":"224","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9861-4139","authenticated-orcid":false,"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108107_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases \u2013 the major drug targets of the twenty-first century","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2026.108107_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib3","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2026.108107_bib4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2026.108107_bib5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.tips.2019.09.002","article-title":"The landscape of atypical and eukaryotic protein kinases","volume":"40","author":"Kanev","year":"2019","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.phrs.2026.108107_bib6","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.3390\/molecules25143226","article-title":"Comparative assessment of protein kinase inhibitors in public databases and in PKIDB","volume":"25","author":"Bournez","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2026.108107_bib7","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41573-025-01147-y","article-title":"Tumour-agnostic kinase inhibitors","volume":"24","author":"Adashek","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2026.108107_bib8","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108107_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105579","article-title":"Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies","volume":"168","author":"Roskoski","year":"2021","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105463","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106037","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update","volume":"175","author":"Roskoski","year":"2022","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106552","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update","volume":"187","author":"Roskoski","year":"2023","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107723","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2025 update","volume":"216","author":"Roskoski","year":"2025","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib17","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1021\/acs.jmedchem.5b01273","article-title":"AXL inhibitors in cancer: a medicinal chemistry perspective","volume":"59","author":"Myers","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2026.108107_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105422","article-title":"Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tips.2022.12.007","article-title":"Futibatinib (Lytgobi) for cholangiocarcinoma","volume":"44","author":"Roskoski","year":"2023","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.phrs.2026.108107_bib21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108107_bib22","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tibs.2015.09.002","article-title":"Dynamics-driven allostery in protein kinases","volume":"40","author":"Kornev","year":"2015","journal-title":"Trends Biochem Sci."},{"key":"10.1016\/j.phrs.2026.108107_bib23","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105660","article-title":"Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes","volume":"169","author":"Roskoski","year":"2021","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib25","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","article-title":"Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification","volume":"9","author":"Hanks","year":"1995","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2026.108107_bib26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/pro.5560030203","article-title":"cAMP-dependent protein kinase: crystallographic insights into substrate recognition and phosphotransfer","volume":"3","author":"Madhusudan","year":"1994","journal-title":"Protein Sci."},{"key":"10.1016\/j.phrs.2026.108107_bib27","doi-asserted-by":"crossref","first-page":"15733","DOI":"10.1021\/bi971438n","article-title":"Participation of ADP dissociation in the rate-determining step in cAMP-dependent protein kinase","volume":"36","author":"Zhou","year":"1997","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2026.108107_bib28","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.bbapap.2009.10.017","article-title":"Defining the conserved internal architecture of a protein kinase","volume":"1804","author":"Kornev","year":"2010","journal-title":"Biochim Biophys. Acta"},{"key":"10.1016\/j.phrs.2026.108107_bib29","doi-asserted-by":"crossref","first-page":"6818","DOI":"10.1073\/pnas.1814279116","article-title":"Defining a new nomenclature for the structures of active and inactive kinases","volume":"116","author":"Modi","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108107_bib30","doi-asserted-by":"crossref","first-page":"D654","DOI":"10.1093\/nar\/gkab920","article-title":"Kincore: a web resource for structural classification of protein kinases and their inhibitors","volume":"50","author":"Modi","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2026.108107_bib31","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108107_bib32","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108107_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2026.108107_bib34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib36","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.phrs.2014.06.001","article-title":"ErbB\/HER protein-tyrosine kinases: structure and small molecule inhibitors","volume":"87","author":"Roskoski","year":"2014","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib37","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib38","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib40","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/17460441.2013.813015","article-title":"The preclinical profile of crizotinib in the treatment of non-small cell lung cancer and other neoplastic disorders","volume":"8","author":"Roskoski","year":"2013","journal-title":"Expert Opin. Drug Dis."},{"key":"10.1016\/j.phrs.2026.108107_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib42","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib44","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2018.04.020","article-title":"The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders","volume":"133","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104725","article-title":"The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias","volume":"155","author":"Roskoski","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib46","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.phrs.2017.04.022","article-title":"ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers","volume":"121","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib47","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib48","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106362","article-title":"Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders","volume":"183","author":"Roskoski","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib50","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2016.09.011","article-title":"Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms","volume":"113","author":"Roskoski","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib52","series-title":"Reference module in life sciences","first-page":"1","article-title":"Src family tyrosine kinases","author":"Frame","year":"2017"},{"key":"10.1016\/j.phrs.2026.108107_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106156","article-title":"Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia","volume":"178","author":"Roskoski","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2016.12.009","article-title":"Allosteric MEK1\/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib55","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.phrs.2016.03.012","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"107","author":"Roskoski","year":"2016","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib56","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.phrs.2012.04.005","article-title":"ERK1\/2 MAP kinases: structure, function, and regulation","volume":"66","author":"Roskoski","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib57","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2019.01.039","article-title":"Targeting ERK1\/2 protein-serine\/threonine kinases in human cancers","volume":"142","author":"Roskoski","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib58","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3390\/biom13101555","article-title":"Navigating the ERK1\/2 MAPK Cascade","volume":"13","author":"Martin-Vega","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.phrs.2026.108107_bib59","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","author":"Roskoski","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib60","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbrc.2010.07.092","article-title":"RAF protein-serine\/threonine kinases: structure and regulation","volume":"399","author":"Roskoski","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2026.108107_bib61","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0968-0896(98)00099-6","article-title":"A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src","volume":"6","author":"Liu","year":"1998","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib62","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu Rev. Biochem."},{"key":"10.1016\/j.phrs.2026.108107_bib63","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.chembiol.2018.05.002","article-title":"Redefining the protein kinase conformational space with machine learning","volume":"25","author":"Ung","year":"2018","journal-title":"Cell Chem. Biol."},{"issue":"D1","key":"10.1016\/j.phrs.2026.108107_bib64","doi-asserted-by":"crossref","first-page":"D552","DOI":"10.1093\/nar\/gkaa945","article-title":"KinaseMD: kinase mutations and drug response database","volume":"49","author":"Hu","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.phrs.2026.108107_bib65","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/bph.13096","article-title":"Ten things you should know about protein kinases: IUPHAR Review 14","volume":"172","author":"Fabbro","year":"2015","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.phrs.2026.108107_bib66","first-page":"197","article-title":"Kinase-centric computational drug development","volume":"50","author":"Kooistra","year":"2017","journal-title":"Ann. Rep. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib67","doi-asserted-by":"crossref","first-page":"10207","DOI":"10.3390\/ijms262010207","article-title":"Using a novel consensus-based chemoinformatics approach to predict ADMET properties and druglikeness of tyrosine kinase inhibitors","volume":"26","author":"Mavridis","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108107_bib68","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrc1097","article-title":"RAS oncogenes: the first 30 years","volume":"3","author":"Malumbres","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.108107_bib69","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ccr.2014.02.017","article-title":"Dragging Ras back in the ring","volume":"25","author":"Stephen","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2026.108107_bib70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108107_bib71","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrc3760","article-title":"Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond","volume":"14","author":"Holderfield","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.108107_bib72","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.3390\/molecules28145359","article-title":"The importance of the pyrazole scaffold in the design of protein kinases inhibitors as targeted anticancer therapies","volume":"28","author":"Nitulescu","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2026.108107_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.177142","article-title":"A comprehensive review of targeting RAF kinase in cancer","volume":"986","author":"Hossain","year":"2025","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.phrs.2026.108107_bib74","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1073\/pnas.79.16.4848","article-title":"Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses","volume":"79","author":"Chang","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108107_bib75","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.6285471","article-title":"Cellular transforming genes","volume":"217","author":"Cooper","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108107_bib76","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jmb.2009.01.041","article-title":"Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains","volume":"387","author":"Williams","year":"2009","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2026.108107_bib77","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.semcdb.2008.07.020","article-title":"The JAK kinases: not just another kinase drug discovery target","volume":"19","author":"Wilks","year":"2008","journal-title":"Semin Cell Dev. Biol."},{"key":"10.1016\/j.phrs.2026.108107_bib78","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.1073\/pnas.91.14.6374","article-title":"Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes","volume":"91","author":"Kawamura","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108107_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106642","article-title":"Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis","volume":"189","author":"Roskoski","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20140712","article-title":"The molecular regulation of Janus kinase (JAK) activation","volume":"462","author":"Babon","year":"2014","journal-title":"Biochem. J."},{"key":"10.1016\/j.phrs.2026.108107_bib81","first-page":"395","article-title":"STATs: an old story, yet mesmerizing","volume":"17","author":"Abroun","year":"2015","journal-title":"Cell J."},{"key":"10.1016\/j.phrs.2026.108107_bib82","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0092-8674(00)81443-9","article-title":"Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA","volume":"93","author":"Chen","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2026.108107_bib83","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1021\/jm901443h","article-title":"Through the \"gatekeeper door\": exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib84","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1039\/C2MD20180A","article-title":"Approaches to discover non-ATP site inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.phrs.2026.108107_bib85","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2026.108107_bib86","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib87","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm400378w","article-title":"KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space","volume":"57","author":"van Linden","year":"2014","journal-title":"J. Med. Chem."},{"issue":"D1","key":"10.1016\/j.phrs.2026.108107_bib88","doi-asserted-by":"crossref","first-page":"D365","DOI":"10.1093\/nar\/gkv1082","article-title":"KLIFS: a structural kinase-ligand interaction database","volume":"44","author":"Kooistra","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"D1","key":"10.1016\/j.phrs.2026.108107_bib89","doi-asserted-by":"crossref","first-page":"D562","DOI":"10.1093\/nar\/gkaa895","article-title":"KLIFS: an overhaul after the first 5 years of supporting kinase research","volume":"49","author":"Kanev","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2026.108107_bib90","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1021\/acschembio.9b00476","article-title":"Surprising non-additivity of methyl groups in drug-kinase interaction","volume":"14","author":"Wienen-Schmidt","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.phrs.2026.108107_bib91","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.2174\/1568026617666170224121313","article-title":"Structure-based virtual screening approaches in kinase-directed drug discovery","volume":"17","author":"Bajusz","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib92","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.phrs.2026.108107_bib93","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2025.06.022","article-title":"The RAS-MEK-ERK pathway in low-grade serous ovarian cancer","volume":"200","author":"Stover","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.phrs.2026.108107_bib94","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO-25-00112","article-title":"Efficacy and safety of avutometinib \u00b1 defactinib in recurrent low-grade serous ovarian cancer: primary analysis of ENGOT-OV60\/GOG-3052\/RAMP 201","volume":"43","author":"Banerjee","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.108107_bib95","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1080\/14796694.2025.2595130","article-title":"The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60\/GOG-3052\/RAMP 201","volume":"21","author":"Banerjee","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.phrs.2026.108107_bib96","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/ijgc-2023-004610","article-title":"Low-grade serous ovarian cancer: expert consensus report on the state of the science","volume":"33","author":"Grisham","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.phrs.2026.108107_bib97","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1136\/ijgc-2024-005305","article-title":"Molecular changes driving low-grade serous ovarian cancer and implications for treatment","volume":"34","author":"Kelliher","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.phrs.2026.108107_bib98","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1158\/0008-5472.CAN-12-3937","article-title":"Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity","volume":"73","author":"Ishii","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2026.108107_bib99","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ygyno.2024.01.028","article-title":"Preclinical efficacy of RAF\/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer","volume":"183","author":"McNamara","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.phrs.2026.108107_bib100","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2024-005919","article-title":"GOG-3097\/ENGOT-ov81\/GTG-UK\/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer","volume":"35","author":"Grisham","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.phrs.2026.108107_bib101","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2107207118","article-title":"Allosteric MEK inhibitors act on BRAF\/MEK complexes to block MEK activation","volume":"118","author":"Gonzalez-Del Pino","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2026.108107_bib102","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jaad.2024.09.048","article-title":"Hand eczema-Part 1: epidemiology, pathogenesis, diagnosis, and work-up","volume":"93","author":"Bissonnette","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.phrs.2026.108107_bib103","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/cod.13804","article-title":"Prevalence, incidence, and severity of hand eczema in the general population - a systematic review and meta-analysis","volume":"84","author":"Quaade","year":"2021","journal-title":"Contact Dermat."},{"key":"10.1016\/j.phrs.2026.108107_bib104","doi-asserted-by":"crossref","first-page":"7928","DOI":"10.1097\/MS9.0000000000004233","article-title":"Delgocitinib in dermatology: a topical pan-JAK inhibitor for chronic hand eczema and atopic dermatitis","volume":"87","author":"Haider","year":"2025","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.phrs.2026.108107_bib105","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/S0140-6736(25)00001-7","article-title":"trial investigators, Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial","volume":"405","author":"Gim\u00e9nez-Arnau","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108107_bib106","article-title":"Pan-JAK inhibition across chronic hand eczema and other cutaneous diseases: an updated review on topical delgocitinib","author":"Termini","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2026.108107_bib107","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1097\/MS9.0000000000003771","article-title":"Delgocitinib 2% cream: a promising FDA-approved therapy for moderate-to-severe chronic hand eczema","volume":"87","author":"Jawaid","year":"2025","journal-title":"Ann. Med Surg."},{"key":"10.1016\/j.phrs.2026.108107_bib108","doi-asserted-by":"crossref","first-page":"7163","DOI":"10.1021\/acs.jmedchem.0c00450","article-title":"Discovery of a Janus kinase inhibitor bearing a highly three-dimensional spiro scaffold: JTE-052 (Delgocitinib) as a new dermatological agent to treat inflammatory skin disorders","volume":"63","author":"Noji","year":"2020","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib109","doi-asserted-by":"crossref","first-page":"7907","DOI":"10.1097\/MS9.0000000000004164","article-title":"Bruton's tyrosine kinase inhibition in ITP: Wayrilz (rilzabrutinib) as a disease-modifying strategy","volume":"87","author":"Hujjat","year":"2025","journal-title":"Ann. Med. Surg."},{"key":"10.1016\/j.phrs.2026.108107_bib110","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/1750743X.2025.2545170","article-title":"Evaluating rilzabrutinib in the treatment of immune thrombocytopenia","volume":"17","author":"Kuter","year":"2025","journal-title":"Immunotherapy"},{"key":"10.1016\/j.phrs.2026.108107_bib111","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1021\/acs.jmedchem.1c01170","article-title":"Discovery of reversible covalent Bruton's tyrosine kinase inhibitors PRN473 and PRN1008 (Rilzabrutinib)","volume":"65","author":"Owens","year":"2022","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib112","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1080\/14656566.2025.2574850","article-title":"Rilzabrutinib and Bruton tyrosine kinase inhibition for the treatment of persistent or chronic immune thrombocytopenia","volume":"26","author":"Moore","year":"2025","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.phrs.2026.108107_bib113","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jaci.2023.12.008","article-title":"BTK signaling-a crucial link in the pathophysiology of chronic spontaneous urticaria","volume":"153","author":"Bernstein","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.phrs.2026.108107_bib114","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jaci.2025.05.030","article-title":"Current and future landscape of Bruton tyrosine kinase inhibitors in allergy","volume":"156","author":"Lin","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.phrs.2026.108107_bib115","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","article-title":"Discovery of LOU064 (Remibrutinib), a potent and highly selective covalent inhibitor of Bruton's tyrosine kinase","volume":"63","author":"Angst","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib116","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40265-025-02170-4","article-title":"Update on the treatment of chronic spontaneous urticaria","volume":"85","author":"Kolkhir","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2026.108107_bib117","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1200\/JCO-25-00275","article-title":"Taletrectinib in ROS1+ non-small cell lung cancer: TRUST","volume":"43","author":"P\u00e9rol","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.108107_bib118","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/fon-2022-1059","article-title":"TRUST-II: a global phase II study of taletrectinib in ROS1-positive non-small-cell lung cancer and other solid tumors","volume":"19","author":"Nagasaka","year":"2023","journal-title":"Future Oncol."},{"key":"10.1016\/j.phrs.2026.108107_bib119","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/13543784.2024.2305131","article-title":"Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data","volume":"33","author":"Nagasaka","year":"2024","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.phrs.2026.108107_bib120","doi-asserted-by":"crossref","unstructured":"Mankar S., Kumbhare M., Chandak S., Gadekar D. Zhongguo Ying Yong Sheng Li Xue Za Zhi, Next-generation targeted therapy: the evolving role of taletrectinib in fusion-positive malignancies, 2025 41:e20250033, https:\/\/doi: \u300810.62958\/j.cjap.2025.033\u3009.","DOI":"10.62958\/j.cjap.2025.033"},{"key":"10.1016\/j.phrs.2026.108107_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102491","article-title":"Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts","volume":"112","author":"Stacchiotti","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2026.108107_bib122","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/S0140-6736(24)00885-7","article-title":"MOTION investigators, Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Gelderblom","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108107_bib123","doi-asserted-by":"crossref","first-page":"143","DOI":"10.5582\/irdr.2025.01010","article-title":"Vimseltinib: a novel colony stimulating factor 1 receptor (CSF1R) inhibitor approved for treatment of tenosynovial giant cell tumors (TGCTs)","volume":"14","author":"Dou","year":"2025","journal-title":"Intractable Rare Dis. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128928","article-title":"Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT)","volume":"74","author":"Caldwell","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2026.108107_bib125","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1158\/1535-7163.MCT-21-0361","article-title":"Vimseltinib: a precision CSF1R therapy for tenosynovial giant cell tumors and diseases promoted by macrophages","volume":"20","author":"Smith","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2026.108107_bib126","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s11912-025-01679-x","article-title":"Medical management of tenosynovial giant cell tumor","volume":"27","author":"Palmerini","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.phrs.2026.108107_bib127","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/2159-8290.CD-24-0306","article-title":"Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers","volume":"15","author":"Wilding","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2026.108107_bib128","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","article-title":"Beamion LUNG-1 Investigators, Zongertinib in previously treated HER2-mutant Non-Small-Cell Lung Cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108107_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104896","article-title":"The development of Zongertinib for HER2-mutant NSCLC","volume":"215","author":"Brazel","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.phrs.2026.108107_bib130","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70272","article-title":"Real-World Prevalence, treatment patterns, and outcomes for patients with HER2 (ERBB2)-mutant metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database","volume":"13","author":"Waliany","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.phrs.2026.108107_bib131","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41698-024-00720-9","article-title":"Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients","volume":"8","author":"Hong","year":"2024","journal-title":"NPJ Precis Oncol."},{"key":"10.1016\/j.phrs.2026.108107_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102671","article-title":"The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: diagnosis and future perspectives","volume":"124","author":"Dorta-Su\u00e1rez","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.phrs.2026.108107_bib133","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118146","article-title":"A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer","volume":"123","author":"Gawli","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib134","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s40265-023-01959-5","article-title":"Sunvozertinib: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2026.108107_bib135","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70091","article-title":"EGFR exon 20-targeting sunvozertinib granted accelerated approval for advanced NSCLC","volume":"131","author":"Lawrence","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2026.108107_bib136","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s10637-025-01588-7","article-title":"Sunvozertinib: a promising oral EGFR inhibitor approved for NSCLC with EGFR Ex20ins mutations","volume":"43","author":"Sangwan","year":"2025","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.phrs.2026.108107_bib137","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11864-020-00779-z","article-title":"Available therapies for patients with neurofibromatosis-related nervous system tumors","volume":"21","author":"Strowd","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.phrs.2026.108107_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106774","article-title":"Rule of five violations among the FDA-approved small molecule protein kinase inhibitors","volume":"191","author":"Roskoski","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib139","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2026.108107_bib140","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: a useful metric for lead selection","volume":"9","author":"Hopkins","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2026.108107_bib141","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2026.108107_bib142","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1021\/acs.jmedchem.8b00077","article-title":"Lipophilic efficiency as an important metric in drug design","volume":"61","author":"Johnson","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib143","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nrd4163","article-title":"The role of ligand efficiency metrics in drug discovery","volume":"13","author":"Hopkins","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2026.108107_bib144","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.addr.2016.01.018","article-title":"Molecular inflation, attrition, and the rule of five","volume":"101","author":"Leeson","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2026.108107_bib145","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib146","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1008130001697","article-title":"Property distribution of drug-related chemical databases","volume":"14","author":"Oprea","year":"2000","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.phrs.2026.108107_bib147","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.1021\/acs.jmedchem.1c00416","article-title":"Target-based evaluation of \"drug-like\" properties and ligand efficiencies","volume":"64","author":"Leeson","year":"2021","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib148","doi-asserted-by":"crossref","first-page":"8091","DOI":"10.1021\/jm300967g","volume":"55","author":"Cui","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib149","first-page":"3559","article-title":"The first general index of molecular complexity","volume":"1103","author":"Bertz","year":"1981","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.phrs.2026.108107_bib150","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1021\/ci00054a004","article-title":"Molecular complexity: a simplified formula adapted to individual atoms","volume":"27","author":"Hendrickson","year":"1987","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"10.1016\/j.phrs.2026.108107_bib151","doi-asserted-by":"crossref","first-page":"7206","DOI":"10.1021\/jm500515d","article-title":"Physicochemical descriptors of aromatic character and their use in drug discovery","volume":"57","author":"Ritchie","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib152","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.drudis.2016.07.007","article-title":"Quality guidelines for oral drug candidates: dose, solubility and lipophilicity","volume":"21","author":"Bayliss","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.phrs.2026.108107_bib153","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd.2018.52","article-title":"Unexplored therapeutic opportunities in the human genome","volume":"17","author":"Oprea","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2026.108107_bib154","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-020-00977-0","article-title":"Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.phrs.2026.108107_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104392","article-title":"The new entries in the therapeutic armamentarium: the small molecule JAK inhibitors","volume":"147","author":"Bechman","year":"2019","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib156","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","article-title":"The infection risks of JAK inhibition","volume":"18","author":"Adas","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.phrs.2026.108107_bib157","article-title":"Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases","volume":"199","author":"Roskoski","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib158","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/ijms22020566","article-title":"The kinase chemogenomic set (KCGS): an open science resource for kinase vulnerability identification","volume":"22","author":"Wells","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108107_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105412","article-title":"Posttranslational modifications as therapeutic targets for intestinal disorders","author":"Choo","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2026.108107_bib160","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","article-title":"Small molecule kinase inhibitor drugs (1995-2021): medical indication, pharmacology, and synthesis","volume":"65","author":"Ayala-Aguilera","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib161","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1021\/acs.jmedchem.0c01511","article-title":"Small-molecule kinase inhibitors for the treatment of nononcologic diseases","volume":"64","author":"Xie","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105806","article-title":"Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS","volume":"172","author":"Roskoski","year":"2021","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib163","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1038\/s41467-021-23165-1","article-title":"Crowdsourced mapping of unexplored target space of kinase inhibitors","volume":"12","author":"Cicho\u0144ska","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2026.108107_bib164","doi-asserted-by":"crossref","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","author":"Min","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.phrs.2026.108107_bib165","doi-asserted-by":"crossref","first-page":"13764","DOI":"10.1002\/anie.201914525","article-title":"New promise and opportunities for allosteric kinase inhibitors","volume":"59","author":"Lu","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.phrs.2026.108107_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107181","article-title":"Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas","volume":"203","author":"Roskoski","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107534","article-title":"Targeted and cytotoxic inhibitors used in the treatment of breast cancer","volume":"210","author":"Roskoski","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib168","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107465","article-title":"Targeted and cytotoxic inhibitors used in the treatment of lung cancers","volume":"209","author":"Roskoski","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2026.108107_bib169","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.phrs.2026.108107_bib170","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/cncr.33933","article-title":"The cure of leukemia through the optimist's prism","volume":"128","author":"Kantarjian","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2026.108107_bib171","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","article-title":"Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.phrs.2026.108107_bib172","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nrd3368","article-title":"Impact of high-throughput screening in biomedical research","volume":"10","author":"Macarron","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2026.108107_bib173","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1021\/jacsau.2c00415","article-title":"The time and place for nature in drug discovery","volume":"2","author":"Young","year":"2022","journal-title":"JACS Au"},{"key":"10.1016\/j.phrs.2026.108107_bib174","doi-asserted-by":"crossref","first-page":"23751","DOI":"10.1021\/acs.jmedchem.5c02863","article-title":"What do oral drugs really look like? Dose regimen, pharmacokinetics, and safety of recently approved small-molecule oral drugs","volume":"68","author":"Brown","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib175","doi-asserted-by":"crossref","first-page":"12918","DOI":"10.1021\/acs.jcim.5c01888","article-title":"CANDID-CNS: AI unlocks stereochemistry and beyond rule of 5 to predict CNS penetration of small molecules","volume":"65","author":"Collins","year":"2025","journal-title":"J. Chem. Inf. Model"},{"key":"10.1016\/j.phrs.2026.108107_bib176","doi-asserted-by":"crossref","first-page":"10207","DOI":"10.3390\/ijms262010207","article-title":"Using a novel consensus-based chemoinformatics approach to predict ADMET properties and druglikeness of tyrosine kinase inhibitors","volume":"26","author":"Mavridis","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108107_bib177","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/d41573-025-00188-7","article-title":"FDA approves 100th small-molecule kinase inhibitor","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2026.108107_bib178","doi-asserted-by":"crossref","DOI":"10.1038\/s41570-022-00451-0","article-title":"Rules were made to be broken","author":"Hartung","year":"2023","journal-title":"Nat. Rev. Chem."},{"key":"10.1016\/j.phrs.2026.108107_bib179","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharm. Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826000228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826000228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T17:14:46Z","timestamp":1772126086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826000228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":179,"alternative-id":["S1043661826000228"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108107","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108107"}}